Genetic Therapies Bootcamp: Foundations, Frontiers, and Clinical Engagement OnDemand-03-10 13-15 318-323 Pearson Session 2 Gene Replacement Therapy

Video Transcription

Video Summary

Dr. Pearson's talk centers on the advances and challenges in gene replacement therapy, focusing on AADC deficiency, a rare neurological disorder caused by dopamine and serotonin synthesis deficits due to a defective gene. Traditional treatments like levodopa are ineffective, but gene therapy delivering functional copies of the gene directly to targeted brain regions shows dramatic improvements in motor and neurological functions, evidenced by patient case studies. He explains differences between in vivo (direct delivery to tissues like the brain) and ex vivo (insertion into stem cells) approaches, highlighting recent FDA-approved therapies for neuromuscular and retinal diseases. The choice of vector, delivery route (systemic, intrathecal, or direct brain injection), dosing, and immune responses are critical factors in therapy success and safety. Challenges such as the blood-brain barrier, immune reactions, and risks of overexpression are discussed, with examples from disorders like Rett syndrome. He emphasizes that therapeutic timing is crucial—earlier treatment typically yields better outcomes, though improvements are possible at various ages. Clinicians play a vital role in patient selection, symptom assessment, and navigating access and cost barriers, which remain significant issues for widespread application. Overall, gene replacement therapies represent a transformative and rapidly evolving landscape in treating rare genetic neurological diseases.

Keywords

AADC deficiency

gene replacement therapy

dopamine synthesis

in vivo gene delivery

FDA-approved gene therapies

blood-brain barrier challenges

therapeutic timing